An in-depth analysis by Treato revealed that in early online conversations there was little recognition of how common the side effects were among women. Women most frequently discussed experiencing debilitating cramping, abnormal bleeding, weight gain, joint pain, migraines, ovarian cysts, hot flashes and night sweats. Women affected by Essure were wondering whether their experience was unique or if others had had similar experiences. By 2010, women are increasingly using social media forums to connect the dots and discovering there were many women experiencing the same side effects as them.
Women’s attitudes about doctors shifted as more information about Essure became available. Before 2006, doctors were rarely blamed when the procedure didn’t go as planned. Women reported that their doctors were telling them that their experience was unique and serious side effects hadn’t been reported. By 2010 women started to blame their doctors for improperly and irresponsibly inserting the device as many doctors couldn’t find the coils they implanted in the women’s bodies. Women discussed filing malpractice suits because they felt their doctors didn’t alert them to Essure’s risks. By 2015 doctors became de-emphasized within online conversations as the blame shifts from doctors to Bayer, the manufacture, and the FDA. When now discussing doctors online, women are discussing trying to find a doctor willing to do a hysterectomy to remove the device.
Nickel allergies became one of the most common sub-topics women were discussing related to Essure. According to Dr. Peter Schalock of Harvard Medical School, the device is 55 percent nickel and 20 percent of women are known to be nickel-allergic. Many women expressed anger at their doctors for not testing them. Women attributed the nickel in the device to the cause of the development of autoimmune disorders that didn’t previously exist as well as reduction of quality of life such as an interruption to their work lives.
“The importance of social data analysis for adverse event reporting is seen through the thousands of online conversations about Essure’s life-altering effects on women,” says Ido Hadari, CEO of Treato. "Regulators need evolve their safety monitoring strategies with the new technologies available so they are accurately seeing the full picture of patients' experiences."
For more information about Treato’s Essure data analysis.
TreatoVoice is a unique data asset that continuously collects and analyzes more than two and a half billion patient and caregiver conversations happening across the Internet in real-time to understand what patients are saying about their experiences with their conditions and treatments. For this data analysis Treato collected more than 17,000 online discussions about Essure from 2002 to present. Through a discourse analysis lens Treato qualitatively reviewed sample sets of posts from three distinct time frames: 2002, 2010 and 2015.